Material Agreement Form 8 K

On July 3, 2024, Elanco Animal Health Incorporated (the "Company") entered into Amendment No. 2 to its Credit Agreement (as amended, the "Credit Agreement"), by and among the Company, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the revolving facility lenders and the issuing banks party thereto, certain exiting revolving facility lenders, JPMorgan Chase Bank, N.A., as revolving facility agent, and Goldman Sachs Bank USA, as term facility agent, collateral agent and security trustee (the "Amendment No. 2"), relating to its senior secured first lien revolving credit facility (the "Revolving Credit Facility").

The Amendment No. 2 extended the maturity date for the Revolving Credit Facility from August 1, 2025 to July 3, 2029 (subject to, if earlier, a springing maturity of 91 days prior to the maturity date of certain long-term indebtedness of the Company and its subsidiaries if, on such date, the aggregate principal amount of such indebtedness equals or exceeds $400 million (subject to certain exceptions)). The Amendment No. 2 also made other amendments to certain other covenants and terms.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Amendment No. 2 filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.